NATIONAL QUALITY FORUM

Measure Evaluation 4.1
January 2010

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The sub-criteria and most of the footnotes from the evaluation criteria are provided in Word comments and will appear if your cursor is over the highlighted area (or in the margin if your Word program is set to show revisions in balloons). Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all yellow highlighted areas of the form. Evaluate the extent to which each sub-criterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the sub-criteria (yellow highlighted areas).

Steering Committee: Complete all pink highlighted areas of the form. Review the workgroup/TAP assessment of the sub-criterion, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met
C = Completely (unquestionably demonstrated to meet the criterion)
P = Partially (demonstrated to partially meet the criterion)
M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)
N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)
NA = Not applicable (only an option for a few sub-criteria as indicated)

(for NQF staff use) NQF Review #: OT3-022-10
NQF Project: Patient Outcomes Measures: Child Health and Mental Health (Phase III)

MEASURE DESCRIPTIVE INFORMATION

De.1 Measure Title: Depression Utilization of the PHQ-9 Tool

De.2 Brief description of measure: Adult patients age 18 and older with the diagnosis of major depression or dysthymia (ICD-9 296.2x, 296.3x or 300.4) who have a PHQ-9 tool administered at least once during the four month measurement period. The Patient Health Questionnaire (PHQ-9) tool is a widely accepted, standardized tool [Copyright © 2005 Pfizer, Inc. All rights reserved] that is completed by the patient, ideally at each visit, and utilized by the provider to monitor treatment progress. This process measure is related to the outcome measures of “Depression Remission at Six Months” and “Depression Remission at Twelve Months”. This measure was selected by stakeholders for public reporting to promote the implementation of processes within the provider’s office to insure that the patient is being assessed on a routine basis with a standardized tool that supports the outcome measures for depression. Currently, only about 20% of the patients eligible for the denominator of remission at 6 or 12 months actually have a follow-up PHQ-9 score for calculating remission (PHQ-9 score < 5).

1.1-2 Type of Measure: process
De.3 If included in a composite or paired with another measure, please identify composite or paired measure
This measure is related to two other measures that are included in this phase III submission for mental health measures. The other measures are 1) Depression Remission at Six Months (outcome) and 2) Depression Remission at Twelve Months (outcome)

De.4 National Priority Partners Priority Area: patient and family engagement
De.5 IOM Quality Domain: effectiveness
De.6 Consumer Care Need: Living With Illness

CONDITIONS FOR CONSIDERATION BY NQF

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td>The measure is in the public domain or an intellectual property (measure steward agreement) is signed.</td>
</tr>
<tr>
<td></td>
<td>Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.</td>
</tr>
<tr>
<td></td>
<td>Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes</td>
</tr>
<tr>
<td>A.1</td>
<td>Proprietary Measure (as defined in measure steward agreement): Yes</td>
</tr>
<tr>
<td>A.2</td>
<td>Measure Steward Agreement: agreement signed and submitted</td>
</tr>
<tr>
<td>A.3</td>
<td>Measure Steward Agreement: agreement signed and submitted</td>
</tr>
<tr>
<td>A.4</td>
<td>Measure Steward Agreement attached: NQF data steward agreement_signed 2009-633982143297548886.pdf</td>
</tr>
<tr>
<td>B.</td>
<td>The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. Yes, information provided in contact section</td>
</tr>
<tr>
<td>C.</td>
<td>The intended use of the measure includes both public reporting and quality improvement. Purpose: public reporting, quality improvement Accountability</td>
</tr>
<tr>
<td>D.</td>
<td>The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. Testing: Yes, fully developed and tested</td>
</tr>
<tr>
<td>D.1</td>
<td>Have NQF-endorsed measures been reviewed to identify if there are similar or related measures? Yes</td>
</tr>
</tbody>
</table>

(for NQF staff use) Have all conditions for consideration been met? Met

Staff Notes to Steward (if submission returned):

Staff Notes to Reviewers (issues or questions regarding any criteria):

Staff Reviewer Name(s):

### 1. IMPORTANCE TO MEASURE AND REPORT

Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)

1a. High Impact

(for NQF staff use) Specific NPP goal:

1a.1 Demonstrated High Impact Aspect of Healthcare: affects large numbers, severity of illness, patient/societal consequences of poor quality

1a.2

1a.3 Summary of Evidence of High Impact: The Centers for Disease Control and Prevention states that nationally 15.7% of people report being told by a health care professional that they had depression at some point in their lifetime. Persons with a current diagnosis of depression and a lifetime diagnosis of depression or anxiety were significantly more likely than persons without these conditions to have cardiovascular
disease, diabetes, asthma and obesity and to be a current smoker, to be physically inactive and to drink heavily. According to National Institute of Mental Health (NIMH), 6.7 percent of the U.S. population ages 18 and older (14.8 million people) in any given year have a diagnosis of a major depressive disorder. Major depression is the leading cause of disability in the U.S. for ages 15 - 44. Additionally, dysthymia accounts for an additional 3.3 million Americans. In Minnesota, the rates for current depression are 6 - 7.9% and the percent of Minnesotans who have a lifetime diagnosis of depression is between 13 and 15%. Suicide rates for Minnesotans are 10.4 per 100,000 or 1.3 suicides per day, with the highest rates among the following groups: males (4 times greater than females), ages 30 to 49 years, and non-hispanic whites.

1a.4 Citations for Evidence of High Impact: 
- Centers for Disease Control and Prevention: Anxiety and Depression Effective Treatments Exist: People with depression and anxiety should seek help as early as possible to reduce health effects and improve quality of life. March 2009. Based on 2006 Behavior Risk Factor Surveillance System www.cdc.gov/Features/dsBRFSSDepressionAnxiety/
- Suicide Prevention Resource Center: Minnesota Suicide Fact Sheet; Suicides 1999 - 2005 www.sprc.org/

1b. Opportunity for Improvement

1b.1 Benefits (improvements in quality) envisioned by use of this measure: 
- Improve the outcomes of symptom control and functioning for patients with major depression and dysthymia. Major depression is a treatable cause of pain, suffering, disability and death, yet primary care providers detect major depression in only 1/3 to 1/2 of their patients with major depression (Schonfeld, 1997 [C]Williams Jr, 2002 [R])
- Improve the frequency of assessment of the response to treatment
- Improve the communication between the primary care and behavioral health providers, have a common tool to document response.
- Use of a standardized tool (PHQ-9) to measure outcomes over time

1b.2 Summary of data demonstrating performance gap (variation or overall poor performance) across providers:
To date, this measure is captured for 92,828 patients with major depression or dysthymia representing 165 clinics in Minnesota. The overall rate of PHQ-9 use in this population is 71.2%. The overall rates by four month measurement periods are as follows:

<table>
<thead>
<tr>
<th>Period</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/1/2008 to 1/31/2009</td>
<td>63.9%</td>
</tr>
<tr>
<td>2/1/2009 to 5/31/2009</td>
<td>75.4%</td>
</tr>
<tr>
<td>6/1/2009 to 9/30/2009</td>
<td>75.6%</td>
</tr>
</tbody>
</table>

Across the participating clinics for the most recent measurement period 6/1/2009 to 9/30/2009:

- Average: 75.6% (24,947/ 32,981)
- Range: 0.0% to 97.9%
- StDev: 23.1

Variation across providers and clinic sites exists as demonstrated in the ranges of scores.

PHQ-9 Utilization Rates for 140 clinics with denominator of 30 or more patients:
- 25% or less: 7.1% (10 clinics)
- 26 to 49%: 11.4% (16 clinics)
- 50 to 74%: 30.0% (42 clinics)
- 75% to 100%: 51.4% (72 clinics)

1b.3 Citations for data on performance gap:
Publicly reported data with clinic level rates is available on the MN HealthScores website www.mnhealthscores.org. Additionally, rates for PHQ-9 utilization will be published in a future edition of the Health Care Quality Report posted on our corporate website at www.mncm.org.

1b.4 Summary of Data on disparities by population group:
Major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment. While the recent increase in treatment is encouraging, inadequate treatment is a serious concern. Emphasis on screening and expansion of treatment
needs to be accompanied by a parallel emphasis on treatment quality. Risk factors for major depression include family or personal history of major depression or substance abuse, recent loss, chronic medical illness, stressful life events that include loss, domestic abuse/violence, traumatic events and major life changes. Although depression can affect any one in their lifetime, adults in the age ranges of 49 to 54 have the highest rates of depression. Other major risk factors include being female, being African-American and living in poverty. Women, regardless of nationality, race, ethnicity or socioeconomic level have twice the rate of depression than men.

Depression in the elderly is widespread, often undiagnosed and usually untreated. It is a common misperception that it is a part of normal aging. Losses, social isolation and chronic medical problems that older patients experience can contribute to depression. The rate of depression in adults older than 65 years of age ranges from 7% to 36% in medical outpatient clinics and increases to 40% in the hospitalized elderly. Comorbidities are more common in the elderly. The highest rates of depression are found in those with strokes (30% to 60%), coronary artery disease (up to 44%), cancer (up to 40%), Parkinson’s disease (40%), and Alzheimer’s disease (20% to 40%). The recurrence rate is also extremely high at 40%

1b.5 Citations for data on Disparities:
ICSI Guideline for Major Depression in Adults in Primary Care 12th edition May 2009
www.icsi.org/guidelines_and_more/gl_os_prot/behavioral_health/depression_5/depression_major_in_adults_in_primary_care_4.html
The Epidemiology of Major Depressive Disorder Results From the National Comorbidity Survey Replication (NCS-R) Ronald C. Kessler, et al JAMA. 2003;289:3095-3105.

1c. Outcome or Evidence to Support Measure Focus

1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): This process measure for using the PHQ-9 tool is directly related to the desired outcomes of demonstrating improvement in symptoms of depression (remission). Our community stakeholders decided to publicly report the process measure in addition to the outcome measures of six and twelve month remission in order to promote the use of the tool and increase the likelihood of obtaining PHQ-9 scores at 6 and 12 month for measurement. Improvement in the symptoms of depression and an ongoing assessment of the current treatment plan is crucial to the reduction of symptoms and psychosocial well being of patients with major depression. Most people treated for initial depression need to be on medication at least six to twelve months after adequate response to symptoms, patients with recurrent depression need to be treated for three years or more and response with psychotherapy can take eight to twelve weeks of regular and frequent therapy to show improvement. Remission is defined as a PHQ-9 score of less than five at twelve months. The Patient Health Questionnaire (PHQ-9) tool is a widely accepted, standardized tool [Copyright © 2005 Pfizer, Inc. All rights reserved] that is completed by the patient, ideally at each visit, and utilized by the provider to monitor treatment progress. This tool was selected for measuring outcomes for this population because it is 1) validated with a sensitivity of .080 and a specificity of 0.92 with substantial heterogeneity I² = 82%, 2) widely accepted and utilized in our state, 3) available for clinical use, 4) translated into many languages and 5) easy for the patient to complete and the provider to score. This nine question tool contains the following questions which are scored on a scale of 0 to 27 based on the scale of Not at All (0), Several Days (1), More Than Half the Days (2), or Nearly Every Day (3) for responses to the questions over the last 2 weeks.
• Little interest or pleasure in doing things
• Feeling down, depressed, or hopeless
• Feeling tired or having little energy
• Poor appetite or overeating
• Feeling bad about yourself — or that you are a failure or have let yourself or your family down
• Trouble concentrating on things, such as reading the newspaper or watching television
• Moving or speaking so slowly that other people could have noticed? Or the opposite — being so fidgety or restless that you have been moving around a lot more than usual
• Thoughts that you would be better off dead or of hurting yourself in some way

1c.2-3. Type of Evidence: cohort study, evidence based guideline, expert opinion, meta-analysis, observational study, randomized controlled trial, other (specify) Consensus Statement

1c.4 Summary of Evidence (as described in the criteria; for outcomes, summarize any evidence that
healthcare services/care processes influence the outcome):

ICSI Guideline Major Depression in Adults in Primary Care 12th Editions- May 2009

Major depression is a treatable cause of pain, suffering, disability and death, yet primary care providers detect major depression in only 1/3 to 1/2 of their patients with major depression (Schonfeld, 1997 [C]; Williams Jr, 2002 [R]). Additionally, more than 80% of patients with depression have a medical comorbidity (Klinkman, 2003 [R]). Usual care for depression in the primary care setting has resulted in only about half of depressed adults getting treated (Kessler, 2005 [C]) and only 20%-40% showing substantial improvement over 12 months (Katon, 1999 [A]; Unutzer, 2002 [A]).

Scope and Target Population:
To assist primary care in developing systems that support effective assessment, diagnosis and ongoing management of new or existing diagnosis of major depression in adults age 18 and over and assist patients to achieve remission of symptoms, reduce relapse and return to previous level of functioning.

Key Objectives of Treatment:
- achieve remission of symptoms in the acute treatment phase for major depression
- reduce relapse and reduction of symptoms
- return patient to previous level of occupational and psychosocial function

Priority Aims:
The aims and measures in this guideline are based upon evidence supporting impact of system elements, process elements, promoting actual symptom and functional patient improvement and outcomes, and are aligned with MN Community Measurement and the DIAMOND Initiative where there is overlap.
1. Increase the accuracy of diagnosis of major depression. (Annotations #1, 2, 3)
2. Improve the frequency of assessment of response to treatment in patients with major depression. (Annotation#12)
3. Improve the outcomes of treatment for major depression. (Annotations #11, 12)
4. Improve the frequency of assessment of patients with major depression for the presence of substance abuse. (Annotations #7, 8)
5. Increase the assessment for major depression of primary care patients presenting with additional high risk conditions such as diabetes, cardiovascular disease, post-stroke, chronic pain and all perinatal women. (Annotation #9, 13)
6. Improve communication between the primary care physician and the mental health care provider (if patient is co managed). (Annotations #8, 11, 14)
7. Decrease the number of completed suicides in patients managed for their depression in primary care. (Annotation #5)

Source: ICSI Guideline for Major Depression can be obtained at: www.icsi.org/guidelines_and_more/gl_os_prot/behavioral_health/depression_5/depression__major__in_adults_in_primary_care_4.html

1c.5 Rating of strength/quality of evidence (also provide narrative description of the rating and by whom):
Institute Clinical Systems Improvement, ICSI Evidence Grading System: www.icsi.org/guidelines_and_more/evidence_grading_system_6/

1c.6 Method for rating evidence: ICSI Evidence Grading System
A. Primary Reports of New Data Collection:
Class A: Randomized, controlled trial
Class B: Cohort study
Class C: Non-randomized trial with concurrent or historical controls, Case-control study, Study of sensitivity and specificity of a diagnostic test, Population-based descriptive study
Class D: Cross-sectional study, Case series, Case report
B. Reports that Synthesize or Reflect Upon Collections of Primary Reports:
Class M: Meta-analysis, Systematic review, Decision analysis, Cost-effectiveness analysis
Class R: Consensus statement, consensus report narrative review
Class X: Medical opinion

Citations are listed in the guideline utilizing the format of (Author, YYYY [report class]).
ICSI Evidence Grading System: www.icsi.org/guidelines_and_more/evidence_grading_system_6/

1c.7 Summary of Controversy/Contradictory Evidence: There is some controversy in the community in regards to the use of the PHQ-9 tool. Though widely accepted and implemented by primary care providers, behavioral specialists (psychiatrists, therapists) were more reluctant to use the PHQ-9 tool to assess the
patient's status and to be measured in general. There has been an ongoing collaborative for behavioral providers the last 2 years to gain understanding and share experiences. There has been significant momentum and acceptance achieved and we currently have both primary care and behavioral health providers submitting data for this measure.

1c.8 Citations for Evidence (other than guidelines): Screening for Depression in Medical Settings with the Patient Health Questionnaire (PHQ) A Diagnostic Meta Analysis. Gilbody, Simon et al Journal of General Internal Medicine Sept 2007

The PHQ-9: Validity of a Brief Depression Severity Measure Kurt Kroenke, MD, Robert Spitzer, MD J Gen Intern Med 2001 16:606-613


1c.9 Quote the Specific guideline recommendation (including guideline number and/or page number):

ICSI Guideline Major Depression in Adults in Primary Care; page # referenced for each section.

The U.S. Preventive Services Task Force (USPSTF) recommends routine depression screening for all adults but only in clinical practices that have systems in place to assure accurate diagnosis, effective treatment and follow-up (U.S. Preventive Services Task Force, 2002 [R]). The purpose of this guideline is to assist ICSI members to develop systems that support effective diagnosis and treatment of major depression. A reasonable way to evaluate whether a system is successfully functioning in its diagnosis, treatment and follow-up of major depression would be to consider the following:

1. Diagnosis: The clinic or medical group should have a mechanism to assure that they are routinely evaluating for and documenting the presence for two weeks of at least five vegetative signs and symptoms of major depression (and that one includes sadness or loss of interest or pleasure in usual activities) in order to substantiate that the patient meets the DSM-IV TR criteria for major depression.

2. The clinic or medical group should have a systematic way to provide and document:
   a. Engagement Education: The patient and his/her family is actively engaged and participating in self-management, based on knowledge of the nature of the disease, risk/benefits of treatment options, and consideration of patient preferences.
   b. Ongoing Contacts: A documented system to assure ongoing contacts with the patient during the first six to twelve months of care (scheduled follow-up appointments, phone calls and some way to react and/or reach out if the patient drops out of treatment) based on use of a standardized, objective tool used at each contact to document and track treatment response.

3. Outcomes: The system should have a way of reliably and consistently monitoring outcomes of individuals and systemwide to improve individual care and the effectiveness of the clinical practice overall. [Page 8]

Screening

If depression is suspected, asking the two-question screen about mood and anhedonia may be as effective as using longer questionnaires:

Over the past month, have you been bothered by:
- Little interest or pleasure in doing things?
- Feeling down, depressed or hopeless?

If the patient answers "yes" to either of the above questions, use a quantitative, standardized instrument to document depressive symptoms and track treatment response (Pignone, 2002 [M]). This is used to supplement but not replace the clinical interview.

Multiple, practical questionnaires with reasonable performance characteristics are available to help clinicians identify and diagnose patients with major depression. In case-finding studies, average questionnaire administration times ranged from less than one minute to five minutes. While the two-question screen is effective with a broad population in primary care, a recent meta-analysis (Gilbody, 2007 [M]) concluded that for high-risk patients, screening with a nine-item Patient Health Questionnaire (PHQ-9) is more valid. The PHQ-9 has been validated for measuring depression severity (Kroenke, 2001 [C]; Spitzer, 1999 [C]). It can be administered telephonically (Pinto-Meza, 2005) and read to the patient. The factor structure of the nine items is comparable when tested with African Americans, Chinese Americans, Latino and non-Hispanic white patient groups (Huang, 2006 [C]). Other language versions that are validated for use in primary care are Spanish (Wulsin, 2002 [C]) and Chinese (Yeung, 2008 [C]). A Thai-language version has also been validated; however, the sensitivity is low (53%). This version could therefore be a useful and reasonable tool to help confirm a suspected depression but less so to screen general populations (Lotrakul, 2008 [C]).

Elderly patients with mild cognitive impairment can reliably fill out the PHQ-9 (Löwe, 2004 [C]).

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
A recent study found the PHQ-9 useful in psychiatric practices, as well. PHQ-9 scores influenced clinical decision-making for 93% of more than 6,000 patient contacts (Duffy, 2008 [C]).

The assessment of major depressive disorders should include the DSM-IV TR numerical rating of the disorder with all five digits, thus including a severity rating. For example, 296.22 (Major depressive disorder, single episode, moderate severity). (American Psychiatric Association, 2000a [Not Assignable])

Depressive Disorder Not Otherwise Specified (Depression NOS), with a diagnosis code of 311 is designed for patients who do not meet criteria for Major Depression Disorder, Dysthmic Disorder, Adjustment Disorder with Depressed Mood or Adjustment Disorder with Mixed Anxiety and Depressed Mood. This is not a homogenous group of patients where there is evidence for best practice. If the patient meets criteria for Major Depressive Disorder or Dysthmic Disorder, it is important to diagnose and code them as such in order to proceed with evidence-based treatment. [Page 14]

Collaborative Care Model

More than 37 randomized controlled trials have demonstrated the effectiveness of the Collaborative Care Model. The work group recommends three key references (Gilbody, 2006 [M]; Hunkeler, 2006 [A]; Katon, 1999 [A]) in which primary care treatment of depression is provided by a team (depression care manager, primary physician, consulting psychiatrist, others). This model has demonstrated improvement in treatment adherence, patient quality of life, and depression outcomes. Preliminary evidence suggests the collaborative care model is also effective for depression during pregnancy and postpartum (Gjerdingen, 2008 [M]).

The design of a team-based collaborative care approach involves:

- primary care providers using evidence-based approaches to depression care and a standard tool for measuring severity, response to treatment plan and remission;
- a systematic way of tracking and reminding patients at appropriate intervals of visits with their primary care physician and monitoring of treatment adherence and effectiveness;
- a team member (care manager role) to utilize the tracking system and make frequent contacts with the patients to provide further education, self-management support, and monitor for response in order to aid in facilitating treatment changes and in relapse prevention; and
- communication between primary care team and psychiatry to consult frequently and regularly regarding patient under clinical supervision, as well as direct patient visits as needed. (Unutzer, 2002 [A]) [Page 26]

Depression Treatment and Follow-Up Intervals Based on Severity

Treatment Recommendation: Education, Pharmacotherapy or psychotherapy. Start treatment and follow up plan, regularly re-evaluate and revise treatment plan.

Follow-up Interval: All depressed patients initially need weekly follow-up (phone or in person) for engagement in treatment, determine if following treatment plan, address side effects, and check if following through on any referrals.

PHQ-9 Score 10 - 14 Moderate - If patient is responding, contacts can extend as far as monthly.
PHQ-9 Score 15-19 Moderately Severe - If patient is responding, contacts can extend to every 2-4 weeks.
PHQ-9 Score >/= 20 Severe - Until significant response is achieved, contacts should remain weekly. Referral to mental health specialist may be warranted by PCP or psychiatrist.

Adapted from Kroenke and Spitzer, Psychiatric Annals 32:9 / September 2002 [Page 37]

If the primary care provider is seeing some improvement, continue working with that patient to augment or increase medication dosage to reach remission. This can take up to three months. Don't give up on the patient whether treating in primary care or referring. Stay connected through consultation or collaboration and take the steps needed to get the patient to remission. This can take longer and can take several medication interventions or other steps. The STAR*D study has shown that primary care can be just as successful as specialty care (Trivedi, 2006a [A]). [Page 37]

Measures

Possible measures of accomplishing this aim:

a. Percentage of patients who have had a response to treatment at six months (+/- 30 days) after initiating treatment, e.g., have a PHQ-9 score decreased by 50% from initial score at six months (+/- 30 days).

b. Percentage of patients who have reached remission at six months (+/- 30 days) after initiating treatment, e.g., have any PHQ-9 score less than 5 at six months (+/- 30 days).

c. Percentage of patients who have had a response to treatment at twelve months (+/- 30 days) after initiating treatment, e.g., have a PHQ-9 score decreased by 50% from initial score at twelve months (+/- 30 days).

d. Percentage of patients who have reached remission at twelve months (+/- 30 days) after initiating treatment.
treatment, e.g., have had any PHQ-9 score less than 5 at twelve months (+/- 30 days). [Page 77]

1c.10 Clinical Practice Guideline Citation: ICSI Institute for Clinical Systems Improvement Health Care Guideline for Major Depression in Adults in Primary Care. 12th Edition May 2009
http://www.icsi.org/guidelines_and_more/gl_os_prot/behavioral_health/depression_5/depression_major_in_adults_in_primary_care_4.html

1c.11 National Guideline Clearinghouse or other URL: Please note that the ICSI guideline referenced is also listed in the National Guideline Clearinghouse but needs to be updated to the May 2009 version. Major depression in adults in primary care. Institute for Clinical Systems Improvement - Private Nonprofit Organization. 1996 Jan (revised 2008 May). 84 pages. [NGC Update Pending] NGC:006525.

1c.12 Rating of strength of recommendation (also provide narrative description of the rating and by whom):
ICSI Scientific Document Development Process located at:
www.icsi.org/guidelines_and_more/document_development_process/

1c.13 Method for rating strength of recommendation (If different from USPSTF system, also describe rating and how it relates to USPSTF):
ICSI's Conclusion Grade definitions parallel with USPSTF ratings of High, Moderate & Low.

CONCLUSION GRADES
Key conclusions (as determined by the work group) are supported by a conclusion grading worksheet that summarizes the important studies pertaining to the conclusion.
Grade I: The evidence consists of results from studies of strong design for answering the question addressed. The results are both clinically important and consistent with minor exceptions at most. The results are free of any significant doubts about generalizability, bias, and flaws in research design. Studies with negative results have sufficiently large samples to have adequate statistical power.
Grade II: The evidence consists of results from studies of strong design for answering the question addressed, but there is some uncertainty attached to the conclusion because of inconsistencies among the results from the studies or because of minor doubts about generalizability, bias, research design flaws, or adequacy of sample size. Alternatively, the evidence consists solely of results from weaker designs for the question addressed, but the results have been confirmed in separate studies and are consistent with minor exceptions at most.
Grade III: The evidence consists of results from studies of strong design for answering the question addressed, but there is substantial uncertainty attached to the conclusion because of inconsistencies among the results from different studies or because of serious doubts about generalizability, bias, research design flaws, or adequacy of sample size. Alternatively, the evidence consists solely of results from a limited number of studies of weak design for answering the question addressed.
Grade Not Assignable: There is no evidence available that directly supports or refutes the conclusion.

1c.14 Rationale for using this guideline over others:
The Institute for Clinical Systems Improvement (ICSI) is a unique organization that is widely respected for its collaborative efforts with guideline development. ICSIs purpose is to help improve patient care in Minnesota through collaboration and innovations in evidence-based medicine. The collaborative is unique in that it brings medical organizations, health plans and business representatives into the decision-making process. Providers in MN are engaged and respect this process and the resulting guideline recommendations.

TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Importance to Measure and Report? 1

Steering Committee: Was the threshold criterion, Importance to Measure and Report, met? Rationale:
Y N

2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)
2a. MEASURE SPECIFICATIONS

S.1 Do you have a web page where current detailed measure specifications can be obtained?
S.2 If yes, provide web page URL:

2a. Precisely Specified

2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome):
Adult patients age 18 and older with the diagnosis of major depression or dysthymia (ICD-9 296.2x, 296.3x or 300.4) who have a PHQ-9 tool administered at least once during the four month measurement period.

2a.2 Numerator Time Window (The time period in which cases are eligible for inclusion in the numerator):
Adult patients age 18 and older with the diagnosis of major depression or dysthymia (ICD-9 296.2x, 296.3x or 300.4) who are either seen in the office or contacted via another method (phone, email) during a four month time period defined by dates of service that fall into that time period, for example 6/1/2009 to 9/30/2009 and have a documented PHQ-9 tool administered as evidenced by at least one PHQ-9 score during that same time period.

2a.3 Numerator Details (All information required to collect/calculate the numerator, including all codes, logic, and definitions):
Adults age 18 and older; no upper age limit
Have the diagnosis of major depression or dysthymia defined by any of the following ICD-9* codes:
296.2x Major depressive disorder, single episode
296.3x Major depressive disorder, recurrent episode
300.4 Dysthymic disorder

* For primary care providers the diagnosis codes can be in any position (primary or secondary). For behavioral health providers the diagnosis codes need to be in the primary position. This is to more accurately define major depression and exclude patients who may have other more serious mental health diagnoses (e.g. schizophrenia, psychosis) with a secondary diagnosis of depression.

Of the patients meeting the above inclusion criteria, the numerator is defined as those patients who had at least one PHQ-9 tool administered during the four month measurement period.
The numerator rate is calculated as follows:
# adult pts with major depression or dysthymia (296.2x, 296.3x or 300.4) with at least one PHQ-9 tool administered during the four month measurement period/
# adult pts with major depression or dysthymia (296.2x, 296.3x or 300.4)

2a.4 Denominator Statement (Brief, text description of the denominator - target population being measured):
Adult patients age 18 and older with the diagnosis of major depression or dysthymia (ICD-9 296.2x, 296.3x or 300.4)

2a.5 Target population gender: Female, Male
2a.6 Target population age range: Age 18 and older

2a.7 Denominator Time Window (The time period in which cases are eligible for inclusion in the denominator):
Adult patients age 18 and older with the diagnosis of major depression or dysthymia (ICD-9 296.2x, 296.3x or 300.4) who are either seen in the office or contacted via another method (phone, email) during a four month time period defined by dates of service that fall into that time period, for example 6/1/2009 to 9/30/2009.

2a.8 Denominator Details (All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions):
Adults age 18 and older; no upper age limit
Have the diagnosis of major depression or dysthymia defined by any of the following ICD-9* codes:
296.2x Major depressive disorder, single episode
296.3x Major depressive disorder, recurrent episode
300.4 Dysthymic disorder
For primary care providers the diagnosis codes can be in any position (primary or secondary). For behavioral health providers the diagnosis codes need to be in the primary position. This is to more accurately define major depression and exclude patients who may have other more serious mental health diagnoses (e.g. schizophrenia, psychosis) with a secondary diagnosis of depression. Patients with the above diagnosis codes who are either seen in the office or contacted via another method (phone, email) during a four month time period defined by dates of service that fall into that time period, for example 6/1/2009 to 9/30/2009.

2a.9 Denominator Exclusions (Brief text description of exclusions from the target population): There are no exclusions for this process measure.

2a.10 Denominator Exclusion Details (All information required to collect exclusions to the denominator, including all codes, logic, and definitions):
There are no exclusions for this process measure.

2a.11 Stratification Details/Variables (All information required to stratify the measure including the stratification variables, all codes, logic, and definitions):
Stratification is not applicable for this process measure.

2a.12-13 Risk Adjustment Type: no risk adjustment necessary

2a.14 Risk Adjustment Methodology/Variables (List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method):
No risk adjustment necessary.

2a.15-17 Detailed risk model available Web page URL or attachment:

2a.18-19 Type of Score: rate/proportion
2a.20 Interpretation of Score: better quality = higher score
2a.21 Calculation Algorithm (Describe the calculation of the measure as a flowchart or series of steps):
This measure is calculated by submitting a count of patients for the denominator and a count of patients in the numerator to a HIPAA secure data portal as part of the process in uploading a detailed patient file to calculate the six and twelve month remission outcome rates. The numerator rate is calculated as follows:
# adult pts with major depression or dysthymia (296.2x, 296.3x or 300.4) with at least one PHQ-9 tool administered during the four month measurement period/
# adult pts with major depression or dysthymia (296.2x, 296.3x or 300.4)
Query processes that medical groups follow to obtain counts:
During the four month measurement period (e.g. dates of service 6/1/2009 to 9/30/2009) how many patients had an office visit or other contact (phone, email) and diagnosis codes for major depression or dysthymia? (296.2x, 296.3x or 300.4). (denominator)
Of these patients, how many had a PHQ-9 tool administered? (numerator)
The counting process is validated during the denominator certification process (where groups document all steps in identifying the depression population). Groups are asked to describe the process they use for obtaining the counts. Denominator documents are reviewed (certified) by MNCM staff prior to data collection and submission. This is to insure that all groups are identifying their population correctly.

2a.22 Describe the method for discriminating performance (e.g., significance testing):
This measure is currently being collected on the full population of eligible patients; therefore significance testing of a sample methodology is not indicated. Of the approximately 165 clinics participating in this measure since September 2008, 97% have an EMR system in place. It is possible for a clinic currently on a paper chart system to use a registry or spreadsheet to track and report this information. Using an EMR with the PHQ-9 summary score as a reportable field does make this data collection more feasible and efficient.

2a.23 Sampling (Survey) Methodology If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):
The measure and its denominator is not based on a sample.

2a.24 Data Source (Check the source(s) for which the measure is specified and tested)
electronic Health/Medical Record, paper medical record/flowsheet, registry data
2a.25 Data source/data collection instrument (Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.):
The data source for this information is the medical record (EMR or registry if on paper chart system) and patient counts are obtained by query.

2a.26-28 Data source/data collection instrument reference web page URL or attachment:

2a.29-31 Data dictionary/code table web page URL or attachment: Attachment Depression DDS Instructional Guide- Partial PHQ-9 Counts.pdf

2a.32-35 Level of Measurement/Analysis (Check the level(s) for which the measure is specified and tested)
Clinicians: Other Clinic Site Level Reporting

2a.36-37 Care Settings (Check the setting(s) for which the measure is specified and tested)
Ambulatory Care: Office, Ambulatory Care: Clinic, Behavioral health/psychiatric unit

2a.38-41 Clinical Services (Healthcare services being measured, check all that apply)
Behavioral Health: Mental Health, Clinicians: Psychologist/LCSW, Clinicians: PA/NP/Advanced Practice Nurse, Clinicians: Physicians (MD/DO), Other Psychiatrist

TESTING/ANALYSIS

2b. Reliability testing

2b.1 Data/sample (description of data/sample and size): To date, this measure is captured for 92,828 patients with major depression or dysthymia representing 165 clinics in Minnesota. The overall rate of PHQ-9 use in this population is 71.2%. This measure was designed for EMR-based full population reporting; there is no sampling of the population. All patients meeting the inclusion criteria are included for rate calculation. However, it is possible for clinics on paper charts systems or with a registry to participate, but it is more labor intensive.

Data reliability is further insured during the denominator certification process, groups are asked to describe how they are querying and/or counting their depression population in providing the numerator and denominator for the calculation of this rate.

2b.2 Analytic Method (type of reliability & rationale, method for testing):
All groups submitting data undergo a denominator certification process to insure that the patient population is being identified and submitted correctly. Data specifications define all fields for the data submission file and include instructions for correct extraction. The data is extracted directly from the EMR and then the outcome rates are calculated based on rules & programming logic. The measure itself is determined to have content validity based on expert panel and workgroups associated with ICSI Adult Major Depression Guideline and the DIAMOND “Depression Improvement Across Minnesota, Offering a New Direction” project. For more information please refer to www.icsi.org/health_care_redesign_/diamond_35953/

2b.3 Testing Results (reliability statistics, assessment of adequacy in the context of norms for the test conducted):
Reliability of data collection methods has been demonstrated through the denominator certification process for all groups submitting data. Sampling or sample size is not an issue for this measure and the rate encompasses the full population.

2c. Validity testing

2c.1 Data/sample (description of data/sample and size): To date, this measure is captured for 92,828 patients with major depression or dysthymia representing 165 clinics in Minnesota. The overall rate of PHQ-9 use in this population is 71.2%. There is significant room for improvement as demonstrated by the ranges of rates below and the fact that currently only about 20% of the eligible denominator patients for the outcome measures of remission at six and twelve months have a PHQ-9 tool administered to determine if remission has occurred. Variation exists across providers and clinic sites as demonstrated by the ranges of scores.
PHQ-9 Utilization Rates for 140 clinics with denominator of 30 or more patients:
25% or less  7.1% (10 clinics)
26 to 49%  11.4% (16 clinics)
50 to 74%  30.0% (42 clinics)
75% to 100%  51.4% (72 clinics)

2c.2 Analytic Method (type of validity & rationale, method for testing):
The measure itself is determined to have content validity based on expert panel and workgroups associated with ICSI Adult Major Depression Guideline and the DIAMOND “Depression Improvement Across Minnesota, Offering a New Direction” project. Experts agreed on the use of a common tool (PHQ-9) and that a score of less than five represented remission or an absence of depression symptoms. For more information please refer to www.icsi.org/health_care_redesign_/diamond_35953/.

2c.3 Testing Results (statistical results, assessment of adequacy in the context of norms for the test conducted):
To date, this measure is captured for 92,828 patients with major depression or dysthymia representing 165 clinics in Minnesota. The overall rate of PHQ-9 use in this population is 71.2%. The overall rates by four month measurement periods are as follows:
10/1/2008 to 1/31/2009:  63.9%
2/1/2009 to 5/31/2009:  75.4%
6/1/2009 to 9/30/2009:  75.6%
Across the participating clinics for the most recent measurement period 6/1/2009 to 9/30/2009:
Average:  75.6% (24,947/ 32,981)
Range:  0.0% to 97.9%
StDev:  23.1
Variation across providers and clinic sites exists as demonstrated in the ranges of scores.
PHQ-9 Utilization Rates for 140 clinics with denominator of 30 or more patients:
25% or less  7.1% (10 clinics)
26 to 49%  11.4% (16 clinics)
50 to 74%  30.0% (42 clinics)
75% to 100%  51.4% (72 clinics)

Low remission (outcome) rates at six and twelve months are in partially related to the medical group’s ability to obtain a PHQ-9 score at six and twelve months +/- 30 days; currently only 20% of the eligible denominator patients have a 6 or 12 month PHQ-9. Groups are diligently working on process improvements in workflow to impact ongoing contact with patients. Results for this measure are available on our public website MN HealthScores at www.mnhealthscores.org.

2d. Exclusions Justified

2d.1 Summary of Evidence supporting exclusion(s):
There are no exclusions for this process measure.

2d.2 Citations for Evidence:
There are no exclusions for this process measure.

2d.3 Data/sample (description of data/sample and size):
There are no exclusions for this process measure.

2d.4 Analytic Method (type analysis & rationale):
There are no exclusions for this process measure.

2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses):
There are no exclusions for this process measure.

2e. Risk Adjustment for Outcomes/ Resource Use Measures

2e.1 Data/sample (description of data/sample and size):
Risk adjustment is not necessary for this process measure. All patients with major depression or dysthymia should be evaluated and assessed on an ongoing basis with a standardized tool.
2e.2 **Analytic Method** *(type of risk adjustment, analysis, & rationale):*
Risk adjustment is not necessary for this process measure.

2e.3 **Testing Results** *(risk model performance metrics):*
Risk adjustment is not necessary for this process measure.

2e.4 If outcome or resource use measure is not risk adjusted, provide rationale: Risk adjustment is not necessary for this process measure. All patients with major depression or dysthymia should be evaluated and assessed on an ongoing basis with a standardized tool.

---

2f. **Identification of Meaningful Differences in Performance**

2f.1 **Data/sample from Testing or Current Use** *(description of data/sample and size):*
This is a fairly new measure for our community and the state of Minnesota. Measures for depression were developed in concert with ICSI during the development of the DIAMOND “Depression Improvement Across Minnesota, Offering a New Direction”. DIAMOND, a new collaborative care management model, was launched in March of 2008. Data collection for the population based depression measures began in September 2008 with some historical data being captured back to dates of service 1-1-2008. Over 165 clinics have participated in the depression measures, one of which is the utilization of the PHQ-9 tool.
Currently we have over 92,800 patients represented in the denominator for this process measure. The overall rate of PHQ-9 use in this population is 71.2%. There is significant room for improvement as demonstrated by the ranges of rates below and the fact that currently only about 20% of the eligible denominator patients for the outcome measures of remission at six and twelve months have a PHQ-9 tool administered to determine if remission has occurred.
Variation exists across providers and clinic sites as demonstrated by the ranges of scores.

PHQ-9 Utilization Rates for 140 clinics with denominator of 30 or more patients:

- 25% or less: 7.1% (10 clinics)
- 26 to 49%: 11.4% (16 clinics)
- 50 to 74%: 30.0% (42 clinics)
- 75% to 100%: 51.4% (72 clinics)

These initial results demonstrate significant opportunity for improvement; one of the most difficult things impacting measurement, but is also reflective in the care and management of patients with depression is maintaining an ongoing connection. One of the reasons for the DIAMOND project’s early success is the care coordination & case manager role with an expectation of frequent contact between patient and provider.

2f.2 **Methods to identify statistically significant and practically/meaningfully differences in performance** *(type of analysis & rationale):*
Results are currently displayed on the public website MN HealthScores at www.mnhealthscores.org and can be ranked in order of performance or by the name of the clinic and comparisons are made to the state average. Historical information for each group is displayed as a run chart to show improvement over time. This measure will also be included in the next version (2010) of the annual Health Care Quality Report located at: www.mncm.org/site/ which incorporates rankings in this report based on percent and confidence intervals.

2f.3 **Provide Measure Scores from Testing or Current Use** *(description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):*
Currently we have over 92,800 patients represented in the denominator for this process measure. The overall rate of PHQ-9 use in this population is 71.2%. There is significant room for improvement as demonstrated by the ranges of rates below and the fact that currently only about 20% of the eligible denominator patients for the outcome measures of remission at six and twelve months have a PHQ-9 tool administered to determine if remission has occurred.
Variation exists across providers and clinic sites as demonstrated by the ranges of scores.

PHQ-9 Utilization Rates for 140 clinics with denominator of 30 or more patients:

- 25% or less: 7.1% (10 clinics)
- 26 to 49%: 11.4% (16 clinics)
- 50 to 74%: 30.0% (42 clinics)

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
### 2g. Comparability of Multiple Data Sources/Methods

2g.1 **Data/sample (description of data/sample and size):** Multiple data sources are not used. The data source for this information is the patient's medical record. No other sources of information are applicable (e.g., is not a claim based measure as serial PHQ-9 scores are needed to calculate this measure). Information can be obtained either from a query of the electronic medical record or via registry or chart abstraction. The measure was designed for full population extraction from an EMR and 97% of the current participating clinics have an EMR in place.

2g.2 **Analytic Method (type of analysis & rationale):**

<table>
<thead>
<tr>
<th>C</th>
<th>P</th>
<th>M</th>
<th>N</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2g.3 **Testing Results (e.g., correlation statistics, comparison of rankings):**

<table>
<thead>
<tr>
<th>C</th>
<th>P</th>
<th>M</th>
<th>N</th>
<th>NA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2h. Disparities in Care

2h.1 **If measure is stratified, provide stratified results (scores by stratified categories/cohorts):** This process measure does not require stratification.

2h.2 **If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans:**

Disparities are not applicable for this process measure, all patients who have major depression or dysthymia are appropriate for having their depression symptoms assessed on an ongoing basis. Potential difficulties can occur if language barriers exist, however as with all health care processes and services, language barriers need to be addressed and frequently this occurs through an interpreter.

### TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Scientific Acceptability of Measure Properties?

<table>
<thead>
<tr>
<th>2</th>
</tr>
</thead>
</table>

### 3. USABILITY

**Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making.** *(evaluation criteria)*

#### 3a. Meaningful, Understandable, and Useful Information

3a.2 **Current Use: in use**

3a.3 **Use in a public reporting initiative (disclosure of performance results to the public at large) (If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). If not publicly reported, state the plans to achieve public reporting within 3 years):**

The PHQ-9 utilization rates for depression are publicly reported by MN Community Measurement on their consumer website located on the MN HealthScores Website at www.mnhealthscores.org. MN Community Measurement is a collaborative effort in our community among those who believe that you cannot improve what you don't measure. Our collaborative includes medical groups, clinics, physicians, hospitals, health plans, employers, consumer representatives and quality improvement organizations. These stakeholders support the notion that greater transparency in our health care system will lead to better health outcomes for the people of Minnesota. MN Community Measurement's mission to accelerate the improvement of health by publicly reporting health care information is having a positive effect on the health care provided in Minnesota. For more information please visit our corporate website at www.mncm.org.

3a.3 **If used in other programs/initiatives (If used in quality improvement or other programs/initiatives, provide follow-up plans):**

<table>
<thead>
<tr>
<th>C</th>
<th>P</th>
<th>M</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
name of initiative(s), locations, Web page URL(s). If not used for QI, state the plans to achieve use for QI within 3 years:
The six month remission measure (related) was the measure selected in our community for pay for performance, Bridges to Excellence and the Minnesota Department of Health Statewide Quality Reporting System for 2011. The PHQ-9 utilization measure, though currently not a part of an external pay for performance program, was selected for public reporting and is available on our website at www.mnhealthscores.org. Use of the data for quality improvement efforts is encouraged and results reporting within the data portal assist groups in understanding potential opportunity for several process and outcome measures for depression. There is a compare function built into the public reporting website so that consumers (or providers) can pick clinics to be compared; additionally medical groups have access to their own detailed patient level results with numerator calculation within our HIPAA secure data portal. Groups can use this information to better understand their depression population in terms of processes and outcomes.

Testing of Interpretability (Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement)
3a.4 Data/sample (description of data/sample and size): Consumer: In November of 2009, Robert Wood Johnson Foundation in conjunction with the Aligning Forces for Quality AF4Q Communities, which includes Minnesota, conducted a study “Producing Online Performance Reports that People Understand” to identify best practices for performance reporting that consumers understand. Six focus groups were conducted that included a total of 50 individuals.
In June of 2007, a series of three consumer focus groups were interviewed (28 individuals) to provide feedback about our old website. A new, enhanced website was launched in 2009 and additional feedback was sought from a focus group (5 individuals)
Providers: August 2008 and August 2009 (102 respondents)
Direct Data Submission Users: July 2009 (96 respondents)

3a.5 Methods (e.g., focus group, survey, QI project):
Feedback was obtained from consumers via focus groups, while surveys were utilized for both provider and direct data submission user feedback.

3a.6 Results (qualitative and/or quantitative results and conclusions):
Consumer:
In November of 2009, Robert Wood Johnson Foundation in conjunction with the Aligning Forces for Quality AF4Q Communities, which includes Minnesota, conducted a study “Producing Online Performance Reports that People Understand” to identify best practices for performance reporting that consumers understand. Six focus groups were conducted that included a total of 50 individuals. The study compared six different AF4Q communities (Minnesota, Detroit, Seattle, Wisconsin, Memphis, Pennsylvania and Maine), Minnesota ranked # 1 for easiest and clearest graphics and the search function which was rated as one of the most important consumer “wants”.
In June of 2007, a series of three consumer focus groups were interviewed (28 individuals) to provide feedback about our old website. Some interesting feedback was obtained about our composite measures: accept responsibility for their own health outcomes, health care quality is not uniform across sites, awareness of the website is low, value having the information available during open enrollment and that the website is fairly easy to use. A new, enhanced website was launched in 2009 and additional feedback was sought from a focus group (5 individuals) that reacted positively about the new search and compare capabilities.
Providers: August 2008- Physicians were involved in the data portal redesign of the results display in terms of what additional information would be useful to them in using the data for quality improvement efforts. Providers liked the enhancements, display of the breakdown of the individual components and ability to download their own group’s specific patient level data for use in further analysis.
August 2009- Survey to medical groups with 102 respondents
* 65% feel that MNCM is selecting measures that drive the most important improvement in health care
* 59% MNCM is accelerating the improvement of care by publicly reporting information
* 67% have visited the new public website MNHealthScores and 74% the corporate website

3b/3c. Relation to other NQF-endorsed measures
3b.1 NQF # and Title of similar or related measures:
NQF # 0105 Title: New Episode of Depression: (a) Optimal Practitioner Contacts for Medication Management, (b) Effective Acute Phase Treatment, (c) Effective Continuation Phase Treatment and NQF # 0418 Title: Screening for Clinical Depression

(for NQF staff use) Notes on similar/related endorsed or submitted measures:

3b. Harmonization
If this measure is related to measure(s) already endorsed by NQF (e.g., same topic, but different target population/setting/data source or different topic but same target population):

3b.2 Are the measure specifications harmonized? If not, why?
The PHQ-9 utilization measure is similar in terms of the target population, however the measures are different. This measure is a process measure related to two other outcome (remission) measures that are also being submitted for NQF consideration during the Phase III call for mental health measures. The existing NQF endorsed measures are related to medication adherence and screening of the general population, and not targeting a standardized tool administered to patients with depression or dysthymia for purposes of assessing treatment outcomes over time.

3c. Distinctive or Additive Value
3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF-endorsed measures:
This measure is similar only in terms of target population; there is no similar measure that is specifying a standardized tool for assessing treatment outcomes over time.

5.1 Competing Measures If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), describe why it is a more valid or efficient way to measure quality:
There is no current NQF endorsed measure that demonstrates the effectiveness of treatment and measures remission (relief of symptoms). This process measure encourages the continued use of a standardized tool for assessment of depression symptoms. Patients who are able to maintain at PHQ-9 score of less than five are demonstrating improved mental health and functional status.

TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Usability?

Steering Committee: Overall, to what extent was the criterion, Usability, met?
Rationale:
4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications?
No

4c.2 If yes, provide justification.

4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences

4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results.
MN Community Measurement has modeled the direct data submission to minimize inaccuracies, errors and unintended consequences. All groups participating sign a terms of use agreement that delineates the group’s responsibilities for submission of data and consequences for not participating in good faith. Additionally all groups sign a Business Associate Agreement that outlines the use of the data. Denominator certification prior to any data collection insures that groups are following the specifications and correctly identifying their population and serves as a point of correction prior to the expenditure of resources for data collection. The submission of patient counts for the calculation of the rates for PHQ-9 utilization is only part of the process in the submission of data for several measures. Additionally, for the overall submission of data, extensive audit processes also support the data’s accuracy. After data submission, in person validation audits are conducted comparing the submission to the patient’s medical record using NCQA’s 8 and 30 rule for audit requiring a 90% accuracy rate. Groups are only allowed three patient records with error out of 30 reviewed in order to achieve 90%. Audits are conducted in the following instances: 1) a random sample of clinics with prior successful submission, 2) for all groups who are new to the submission process, 3) a group who has had a change in system or process (e.g. went from paper charts to EMR) since the last submission or 4) any group with a history of prior unsuccessful audit. It has been our experience that the post submission audits have identified both issues with data extraction programming from an EMR and abstraction errors when data is collected from the chart. Groups have been amenable to remedy plans, resubmission and re-audit.

4e. Data Collection Strategy/Implementation

4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/implementation issues:
Over the last three years during the direct data submission process for three measures (Optimal Diabetes Care, Optimal Vascular Care and Depression Measures) we have learned the following:
1. Data Submission- Providing data collection software for medical groups wishing to submit data was not always the best and most efficient way of collecting data. As electronic health records use becomes more pervasive in our state, providing templates of data file submissions proved to be more efficient.
2. Specifications- Detailed specifications with instructions on how to handle most situations (e.g. detailed instructions on blood pressure values) has been valuable to medical groups, increased data accuracy and resulted in 98% of groups submitting data successfully.
3. Audit- Audit methods have insured the accuracy of our data and we are able to successfully compare providers because everyone is pulling their data the same way and subject to the same rules.
4. Confidentiality- Patient confidentiality has been addressed by numerous mechanisms. MN Community only receives the patient level information needed to calculate the rates, determine eligibility for inclusion in the measure and support the administration of pay for performance programs. The PHI submitted is minimal and the data is protected by 1) password protection with password only available to the medical group submitting data, 2) file upload process is encrypted as data is transferred and 3) Data is stored on a separate secure server and meets all HIPAA protection rules.
6. Acceptance of Data- Vast improvement in terms of the timeliness of the data submitted by medical groups six weeks after the end of the measurement period as compared to prior method of health plan’s samples and the results over a year old. Providers are more accepting of the results as compared to previous methods of pooling health plan samples.
7. Data Collection Burden- We have learned that for additional future measures we will need to stagger the data collection time frames and submission deadlines as to not burden the medical groups in terms of abstraction/ extraction (e.g. can’t always have a measurement period Jan 1st to Dec 31st reported the second week of February, may need to consider July 1st to June 30th with data submission in August)
8. Health Plans: pay for performance and the inclusion of measures within contracts significantly impacts the
number of groups participating in each measure.

4e.2 Costs to implement the measure (costs of data collection, fees associated with proprietary measures): Medical Groups: There are no fees charged to medical groups to submit their data to MNCM. There are no fees for the procurement and use of the PHQ-9 tool. Data collection costs (staff time to write an extract program from EMR) are absorbed by the medical groups submitting data. Clinics that have the PHQ-9 tool embedded in their EMR and the total score as a reportable field are more efficient than clinics that do not have these features.

Administrative (Costs to MNCM): Costs are associated with staffing. Currently, there is one full time project manager and one part time project coordinator dedicated to the direct data submission project and services for validation audits are contracted with abstractor during a 4 - 6 week period each year. Responsibilities include creation and annual update of the direct data submission guide, recommendations for data portal enhancements, communication to users, denominator certification, training of auditors for validation, availability for all questions & problems related to specs and submission, planning and performing some of the validation audits and approving data for publication.

It is estimated that the startup costs for the development of our data portal was approximately $25,000 for both the diabetes and ischemic vascular composite measures; additional costs of $10,000 were incurred to add multiple depression measures.

4e.3 Evidence for costs:
MNCM contracts with portal vendor (historical) and budget.
Staff’s experience with data collection at numerous clinic sites.

4e.4 Business case documentation: Prior to implementing the direct data submission process for the depression measures, MN Community Measurement and it stakeholders knew there was great variability in the care and management that was being provided to patients with depression and initial results for remission at six months demonstrated very low overall rates and significant room for improvement. Groups were not experienced in collecting data for depression, however over 400 primary care clinics were already used to collecting and submitting data for two composite measures for diabetes and vascular disease and demonstrated success with the DDS Direct Data Submission process.

<table>
<thead>
<tr>
<th>TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria for Feasibility?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steering Committee:</strong> Overall, to what extent was the criterion, Feasibility, met?</td>
</tr>
<tr>
<td>Rationale:</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>RECOMMENDATION</strong></td>
</tr>
<tr>
<td>(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.</td>
</tr>
<tr>
<td>Time-limited</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Steering Committee:</strong> Do you recommend for endorsement?</td>
</tr>
<tr>
<td>Comments:</td>
</tr>
<tr>
<td>Y</td>
</tr>
</tbody>
</table>

**CONTACT INFORMATION**

Co.1 **Measure Steward (Intellectual Property Owner)**
Co.1 **Organization**
MN Community Measurement | 3433 Broadway Street NE, Suite # 455 | Minneapolis | Minnesota | 55413

Co.2 **Point of Contact**
Anne | Snowden, MPH, CPHQ | snowden@mncm.org | 612-454-4811

Co.3 **Organization**

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
**MN Community Measurement | 3433 Broadway Street NE, Suite # 455 | Minneapolis | Minnesota | 55413**

**Co.4 Point of Contact**  
Anne | Snowden, MPH, CPHQ | snowden@mncm.org | 612-454-4811

**Co.5 Submitter If different from Measure Steward POC**  
Collette | Pitzen, RN, BSN, CPHQ | pitzen@mncm.org | 612-454-4815 | MN Community Measurement

**Co.6 Additional organizations that sponsored/participated in measure development**  
ICSI - Institute for Clinical Systems Improvement

### ADDITIONAL INFORMATION

**Workgroup/Expert Panel involved in measure development**

Ad.1 Provide a list of sponsoring organizations and workgroup/panel members’ names and organizations. Describe the members’ role in measure development.

- Nancy Jaeckels - Institute for Clinical Systems Improvement, Vice President Member Relations & Strategic Initiatives
- Katrina Beckstrom - HealthPartners - Care Innovation & Measurement, Senior Quality Coordinator
- Michael Trangle, MD - HealthPartners Clinics/ Regions Hospital, Associate Medical Director
- Kenneth Joslyn, MD - Medica Health Plan, Medical Director Quality and Population Health
- Jim Chase - MN Community Measurement, President
- Diane Mayberry - MN Community Measurement, Chief Operating Officer
- Anne Snowden - MN Community Measurement, Director of Performance Measurement & Reporting
- Carrie Trygstad - MN Community Measurement, Project Manager

This group worked in concert with the ICSI DIAMOND project for measure development; the original charter of the workgroup includes:

- Develop population-wide, ambulatory care measures(s) of the quality of care for patients diagnosed with Depression, consistent with the work of the ICSI DIAMOND project.
  - Process measures (i.e.: quality of coding, depression screening, completion of PHQ-9 survey, 3 month follow-up visit)
  - Outcome measures (response and remission rates)
- Develop direct data collection, submission and reporting plan
  - Physicians and non-physicians
  - Primary care and Behavioral Health Care

Ad.2 If adapted, provide name of original measure: The measure is not adapted.

Ad.3-5 If adapted, provide original specifications URL or attachment:

**Measure Developer/Steward Updates and Ongoing Maintenance**

- Ad.6 Year the measure was first released: 2008
- Ad.7 Month and Year of most recent revision: 2009-12
- Ad.8 What is your frequency for review/update of this measure? Annual
- Ad.9 When is the next scheduled review/update for this measure? 2010-12

Ad.10 Copyright statement/disclaimers: © MN Community Measurement, 2009. All rights reserved

PHQ-9: Copyright © 2005 Pfizer, Inc. All rights reserved

Ad.11-13 Additional Information web page URL or attachment:

**Date of Submission (MM/DD/YY): 01/29/2010**